bioRxiv preprint doi: https://doi.org/10.1101/2020.10.20.346916; this version posted October 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Isolation of cross-reactive monoclonal antibodies against divergent human 2 coronaviruses that delineate a conserved and vulnerable site on the spike 3 protein 4 5 6 Chunyan Wanga, Rien van Haperenb,c, Javier Gutiérrez-Álvarezd, Wentao Lia, Nisreen 7 M.A. Okbae, Irina Albulescua, Ivy Widjajaa,‡, Brenda van Dierena,‡, Raul Fernandez- 8 Delgadod, Isabel Solad, Daniel L. Hurdissa, Olalekan Daramolaf, Frank Grosveldb,c, 9 Frank J.M. van Kuppevelda, Bart L. Haagmanse, Luis Enjuanesd, Dubravka Drabekb,c 10 and Berend-Jan Boscha,* 11 12 Division of Infectious Diseases and Immunology, Department of Biomolecular Health 13 Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlandsa; 14 Department of Cell Biology, Erasmus Medical Center, Rotterdam, the Netherlandsb; 15 Harbour BioMed, Rotterdam, the Netherlandsc; Department of Molecular and Cell 16 Biology, National Center for Biotechnology-Spanish National Research Council (CNB- 17 CSIC), Madrid, Spaind; Department of Viroscience, Erasmus Medical Center, 18 Rotterdam, the Netherlandse; Cell Culture and Fermentation Sciences, 19 Biopharmaceutical Development, BioPharmaceuticals R&D, AstraZeneca, Cambridge, 20 United Kingdomf. 21 22 ‡ Present address: Merus N.V., Utrecht, the Netherlands. 23 * Address correspondence to Berend-Jan Bosch (
[email protected]) 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.10.20.346916; this version posted October 20, 2020.